LIDCO GROUP PLC

("LiDCO" or the "Company")

LiDCOrapid Registration Japan

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, is pleased to announce that Argon Medical (LiDCO's partner in Japan)  has confirmed that the LiDCOrapid Monitor and associated disposable products have been successfully approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). LiDCO believes that Japan is the second largest market in the world for hemodynamic monitoring with approximately 680,000 high-risk surgical patients per annum who would benefit clinically from improved intraoperative fluid management.

The LiDCO products will be shown at the forthcoming Japanese Anesthetic Society Meeting in Kobe on the 7^th - 9^th of June.

Dr Terry O'Brien, CEO of LiDCO, commented: "We are delighted that our partner Argon Medical has successfully concluded the approval process in Japan and will be promoting the product in the very near future. Minimally invasive hemodynamic monitoring in Japan has a potential market value of US$285 million per annum. We greatly welcome the substantial market opportunity this presents for LiDCO's fluid monitoring technology."

George A. Leondis, President of Argon Medical Devices, Inc added: "We are  pleased to have received this most important approval. This next generation technology expands our critical care portfolio, offering clinicians a versatile, new and more effective option in minimally invasive, hemodynamic monitoring."

- Ends -

For further information, please contact:

Media enquiries:

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery.  These benefits are:

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.

* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*  LiDCO's Distribution Network:

The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.